DrugPatentWatch Database Preview
MINOCIN Drug Profile
see a sample report or, see our see our flat-rate plans
When do Minocin patents expire, and when can generic versions of Minocin launch?
This drug has twenty-seven patent family members in twenty-one countries.
The generic ingredient in MINOCIN is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
Summary for MINOCIN
| International Patents: | 27 |
| US Patents: | 2 |
| Applicants: | 4 |
| NDAs: | 5 |
| Suppliers / Packagers: | 4 |
| Bulk Api Vendors: | 71 |
| Clinical Trials: | 32 |
| Patent Applications: | 4,346 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MINOCIN at DailyMed |
Pharmacology for MINOCIN
| Ingredient-type | Tetracyclines |
| Drug Class | Tetracycline-class Drug |
Medical Subject Heading (MeSH) Categories for MINOCIN
Synonyms for MINOCIN
| (2E,4S,4aR,5aS,12aR)-2-(amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3 ,12-trione |
| (2E,4S,4AS,5AR,12AS)-2-[AMINO(HYDROXY)METHYLIDENE]-4,7-BIS(DIMETHYLAMINO)-10,11,12A-TRIHYDROXY-1,2,3,4,4A,5,5A,6,12,12A-DECAHYDROTETRACENE-1,3,12-TRIONE |
| (2E,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione |
| (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione |
| (4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione |
| (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE |
| (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide |
| (4S,4aS,5aR,12aS)4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide;(4S,4aS,5aR,12aS)4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydro |
| 10118-90-8 |
| 1071761-03-9 |
| 13614-98-7 (mono-hydrochloride) |
| 1371-EP2269978A2 |
| 1371-EP2269985A2 |
| 1371-EP2269991A2 |
| 1371-EP2272832A1 |
| 1371-EP2284150A2 |
| 1371-EP2284151A2 |
| 1371-EP2284152A2 |
| 1371-EP2284153A2 |
| 1371-EP2284155A2 |
| 1371-EP2284156A2 |
| 1371-EP2284164A2 |
| 1371-EP2287140A2 |
| 1371-EP2287148A2 |
| 1371-EP2287150A2 |
| 1371-EP2289871A1 |
| 1371-EP2292590A2 |
| 1371-EP2292612A2 |
| 1371-EP2295402A2 |
| 1371-EP2295419A2 |
| 1371-EP2295426A1 |
| 1371-EP2295427A1 |
| 1371-EP2298732A1 |
| 1371-EP2301534A1 |
| 1371-EP2301912A2 |
| 1371-EP2301913A1 |
| 1371-EP2301914A1 |
| 1371-EP2301916A2 |
| 1371-EP2305637A2 |
| 1371-EP2308832A1 |
| 1371-EP2308863A1 |
| 1371-EP2311451A1 |
| 1371-EP2311796A1 |
| 1371-EP2311797A1 |
| 1371-EP2311798A1 |
| 1371-EP2311799A1 |
| 1371-EP2316450A1 |
| 146440-73-5 |
| 17175-40-5 |
| 18M908 |
| 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S-(4alpha,4aalpha,5aalpha,12aalpha))- |
| 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- |
| 24058-90-0 |
| 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide |
| 7-Dimethylamino-6-demethyl-6-deoxytetracycline |
| AB00053501_04 |
| AB00053501_05 |
| AB00053501-03 |
| AC1L2NSN |
| AC1NQXWM |
| AC1NSG0A |
| AJ-65483 |
| AK322058 |
| Akamin |
| Aknemin |
| AKOS015969674 |
| Alti-Minocycline |
| AM20090714 |
| API0003397 |
| Apo-Minocycline |
| Arestin |
| BCBcMAP01_000027 |
| BCP9000928 |
| BDBM50103599 |
| Bio-0062 |
| Borymycin |
| BRN 3077644 |
| BSPBio_002035 |
| C07225 |
| C23H27N3O7 |
| CAS-10118-90-8 |
| CHEBI:50694 |
| CHEMBL1434 |
| CHEMBL259172 |
| CL 59806 |
| CRL-1605 & Minocycline |
| D05045 |
| D08LTU |
| DB01017 |
| DivK1c_000450 |
| DSSTox_CID_25033 |
| DSSTox_GSID_45033 |
| DSSTox_RID_80650 |
| DTXSID1045033 |
| DYKFCLLONBREIL-KVUCHLLUSA-N |
| Dynacin |
| FT-0628949 |
| FYY3R43WGO |
| Gen-Minocycline |
| HMS2090D03 |
| HSDB 3130 |
| IDI1_000450 |
| J-500789 |
| KBio1_000450 |
| KBio2_001447 |
| KBio2_004015 |
| KBio2_006583 |
| KBio3_001535 |
| KBioGR_000583 |
| KBioSS_001447 |
| Klinomycin |
| KSC-12-231B |
| KUC106429N |
| Lactoferrin B & Minocycline |
| Lactoferrin H & Minocycline |
| LMPK07000002 |
| LS-93850 |
| MINO |
| Mino-Tabs |
| Minociclina |
| Minociclina [INN-Spanish] |
| minociclinum |
| Minocin (Hydrochloride) |
| Minocin (TN) |
| Minocline |
| Minocyclin |
| minocycline |
| Minocycline (USAN/INN) |
| Minocycline [USAN:BAN:INN] |
| Minocycline [USAN:INN:BAN] |
| Minocycline Monohydrochloride |
| Minocyclinum |
| Minocyclinum [INN-Latin] |
| Minocyn |
| Minoderm |
| Minoz |
| MIY |
| MolPort-020-005-814 |
| NCGC00178854-01 |
| NCGC00183044-01 |
| NCGC00188954-01 |
| NINDS_000450 |
| Novo-Minocycline |
| NSC 141993 |
| NSC141993 |
| PL009220 |
| PL045106 |
| Prestwick0_000315 |
| Prestwick1_000315 |
| Prestwick2_000315 |
| SBI-0051449.P003 |
| SCHEMBL16681149 |
| SCHEMBL24315 |
| SCHEMBL4042 |
| Sebomin |
| SMP1_000191 |
| Solodyn |
| SPBio_000974 |
| SPBio_002529 |
| Spectrum_000967 |
| Spectrum2_001047 |
| Spectrum3_000508 |
| Spectrum4_000062 |
| Spectrum5_001293 |
| Tox21_113643 |
| Tri-minocycline |
| UNII-FYY3R43WGO |
| Vectrin |
| Vectrin (Hydrochloride) |
| ZINC100409820 |
| ZINC14879992 |
| ZINC4019704 |
US Patents and Regulatory Information for MINOCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precision Dermat | MINOCIN | minocycline hydrochloride | CAPSULE;ORAL | 050649-001 | May 31, 1990 | AB | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Rempex Pharms | MINOCIN | minocycline hydrochloride | INJECTABLE;INJECTION | 050444-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Triax Pharms | MINOCIN | minocycline hydrochloride | CAPSULE;ORAL | 050315-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Rempex Pharms | MINOCIN | minocycline hydrochloride | INJECTABLE;INJECTION | 050444-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Non-Orange Book US Patents for MINOCIN
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,744,179 | Tetracycline compositions | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for MINOCIN
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 102970992 | ➤ Try a Free Trial |
| European Patent Office | 2568987 | ➤ Try a Free Trial |
| Portugal | 2568987 | ➤ Try a Free Trial |
| Japan | 2013529201 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
